礼来(LLY)
搜索文档
Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Seeking Alpha· 2024-11-28 21:30
JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks. He focuses on identifying growth investing opportunities that present the most attracti ...
Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?
The Motley Fool· 2024-11-28 20:30
Eli Lilly (LLY -0.14%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion. But in recent weeks, its share price has been falling. And now the stock is down over 20% from its 52-week high of $972.53. Could this be a great time to add the high-powered healthcare stock to your portfolio?Why is Eli Lilly stock struggling of late?Eli Lilly has been a fantastic growth stock to own in recent years. Entering trading this week, its five-year returns have totaled m ...
LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs
ZACKS· 2024-11-27 23:50
Shares of Eli Lilly (LLY) and Novo Nordisk (NVO) were up on Tuesday, likely due to a proposal by President Biden that Medicare and Medicaid should cover the cost of obesity treatments. The new proposal, if passed, will significantly expand access for Lilly and Novo Nordisk’s currently marketed weekly injections to treat obesity, Zepbound and Wegovy, respectively. Zepbound is marketed as Mounjaro and Wegovy as Ozempic for type II diabetes. Both Mounjaro and Ozempic are also prescribed by doctors off-label fo ...
The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now
The Motley Fool· 2024-11-27 17:35
Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue growth thanks to the fact that patients need their medicines -- so will continue with them no matter what the economy is doing. A top pharma stock also may have one particular star product that brings in blockbuster revenue, and this growth could drive stock performance. Finally, pharma stocks often pay dividends, an extra bonus to ensure that every year you'll generate income from this ...
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
Benzinga· 2024-11-27 07:45
STOCK RISES OVER 2.8% AT ITS HIGH FOR THE DAYToday, at 10:21 AM on November 26th, a significant trading signal occurred for Eli Lilly & Company LLY as it demonstrated a Power Inflow at a price of $784.63. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Lilly’s stock, marking a potential ...
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs
Investopedia· 2024-11-27 02:20
Key TakeawaysEli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' weight-loss drugs in government-backed healthcare plans.The proposal recommended drugs like Ozempic and Mounjaro be covered under Medicare and Medicaid, making them more accessible to millions of new patients.The White House said the changes could also lower costs of the drugs. Eli Lilly (LLY) and Novo Nordisk (NVO) shares rose Tuesday after the Biden administration propos ...
Eli Lilly: Steep Pullback, Still Compelling Here
Seeking Alpha· 2024-11-24 00:45
文章无实质公司和行业内容 - 文档未涉及公司和行业相关内容,无法按照要求总结 [1][2][3][4]
Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?
The Motley Fool· 2024-11-23 23:00
公司股价表现 - 制药巨头礼来公司(Eli Lilly)上半年股价高涨但自6月1日起失去部分动力股价下跌11% [1] - 尽管股价下跌但仍受华尔街投资者青睐千禧管理公司(Millennium Management)在第三季度对礼来的持股增加了86% [1] 公司业绩表现及股价下跌原因 - 自6月1日起礼来有新药品获批且有药品有积极数据报告第二季度业绩向上调整指引但下半年表现不佳 [2] - 股价看起来昂贵其远期市盈率为54.8远高于标准普尔500指数的22和医疗保健行业的17.4 [3] - 礼来股价之前涨势迅猛一些投资者可能在股价下跌前获利了结 [4] - 第三季度营收同比增长20%至114亿美元但未达投资者预期且略微下调2024年全年指引导致股价进一步下跌 [5] 公司未来发展潜力 - 公司的替尔泊肽(tirzepatide)品牌名为Mounjaro(用于糖尿病)和Zepbound(用于体重管理)在第三季度销售额合计达44亿美元且有多项潜在新适应症的积极数据 [6] - 替尔泊肽是一种双重激动剂分析师称其销售额峰值可能达到250亿美元 [8] - 除替尔泊肽外其他新药如Kisunla等在未来五年内将产生重大影响例如Omvoh到2029年销售额可能达12亿美元 [9] - 未来几年公司在研发管线方面将取得重大进展如候选药物retatrutide是一种三重激动剂 [10][11] 公司估值分析 - 公司远期市盈率较高但考虑到市场预期如果公司能达到预期估值可能不是大问题 [12] - 第三季度调整后每股收益(EPS)飙升至1.18美元相比去年同期的0.10美元明年分析师预计EPS将增长近72% [12][13] - 尽管远期市盈率高但考虑到公司发展前景仍值得投资建议跟随亿万富翁Englander的投资决策 [13]
2 Incredible Growth Stocks to Buy With $1,000 Right Now
The Motley Fool· 2024-11-23 19:15
It's always a great time to invest in quality businesses that can prime your portfolio for long-term growth. It's important to be selective with the companies that you add to your portfolio and ensure that you only put cash into investments that align with your overall investment priorities, risk tolerance, and long-term goals.You should also only put cash to work that you can leave in your portfolio for a few years, not funds that you might soon need for bills or other financial obligations. On that note, ...
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Benzinga· 2024-11-22 01:47
公司股价表现 - 公司股票去年上涨26.04%但近期表现不佳上个月下跌17.57% [1] - 公司股票远低于夏季高点当前交易价格为746.94美元 [2] - 公司股票低于8日20日和50日指数移动平均线处于看跌趋势相对强弱指数33.02表明接近超卖区域MACD为 - 37.55确认强烈下行势头 [3] - 公司股票200日简单移动平均线835.76美元现在已成为遥远记忆加剧担忧 [4] 股价下跌原因 - 抗肥胖药物制造商整体抛售与担心唐纳德·特朗普当选总统后可能任命小罗伯特·F·肯尼迪为卫生与公众服务部部长有关 [5] - 投资者担心他对GLP - 1减肥治疗的批评立场可能导致保险覆盖范围减少或定价压力 [6] 公司基本面情况 - 公司的Zepbound和Mounjaro销售额预计到2026年将达到180亿美元较2024年估计值翻倍 [7] - 到2026年总营收预计攀升至690亿美元每股收益飙升至30美元是当前13.26美元的两倍多 [7] - 按33.2倍的预期市盈率计算该股票估值较7月峰值的57.2倍更具吸引力 [7] 不同观点 - 对于反向投资者基本面呈现不同情况 [7] - 吉姆·克莱默认为现在这只股票像不久前被喜爱一样被厌恶他认为这是一个买入机会 [8] - 对于长期投资者公司在新兴肥胖药物市场的主导地位仍然是一个引人注目的增长故事 [8] - 抛售是危险信号还是黄金机会可能取决于投资者对基本面的信心 [8]